US Senators Seek 'Clarity’ On Middlemen Obstructing List Price Reductions

04 Jul 2018

Letters to several pharmacy benefit managers and wholesalers request information on whether middlemen have discouraged decrease in list prices.

something in your way barrier illustration design over a white background

Democratic Senators Elizabeth Warren, Mass., and Tina Smith, Minn., have written to nine pharmacy benefit managers and wholesalers to investigate whether they are discouraging biopharmaceutical manufacturers from list price reductions because it would result in lower fees and rebates for the middlemen.

The June 29 letters went to: the PBMs Express Scripts Holding Co., CVS Health Corp., OptumRx Inc.,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

US Budget Bill Eases IRA Price Controls But Coverage Losses Will Impact Pharma

04 Jul 2025

• By Cathy Kelly

The legislation expected to be signed by President Trump is a mixed bag for pharmaceutical manufacturers depending on their product mix and manufacturing situation.

Kennedy Appears Ill-Informed On Major Pharma Priorities, Creating Unique Lobbying Dynamics

04 Jul 2025

• By Sarah Karlin-Smith

The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.